Canada closely following reports of plague in Russia, health minister says - The Spec

OTTAWA — Health Minister Marjorie Michel says Canada is very closely following reports that a woman who worked at a plague research institute in Siberia has died. Russian authorities say the woman contracted pneumonia from an unknown source and there’s no evidence it was caused by any of the pathogens she worked with.

This undated photo released in 2019 by the Irkutsk Anti-Plague Research Institute of Siberia and Far East, shows the institute workers in a lab. OTTAWA - Canada is very closely following reports that a woman who worked at a plague research institute in Siberia has died, Health Minister Marjorie Michel said on Monday. Russian authorities say the woman contracted pneumonia from an unknown source. They also say there’s no evidence it was caused by any of the pathogens she worked with at the Irkutsk Anti-Plague Research Institute of Siberia and the Far East.

OTTAWA — Canada is very closely following reports that a woman who worked at a plague research institute in Siberia has died, Health Minister Marjorie Michel said on Monday. Russian authorities say the woman contracted pneumonia from an unknown source. They also say there’s no evidence it was caused by any of the pathogens she worked with at the Irkutsk Anti-Plague Research Institute of Siberia and the Far East.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.